Baoning Wang1, Jing Yang2, Suizhong Cao3, Hongren Wang1, Xing Pan4, Jie Zhu5, Yongjun Zhou5, Lizhen Gao5, Wanyi Li1, Mingyuan Li1. 1. Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China. 2. Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China ; Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China ; Department of Medical Microbiology, School of Preclinical Medicine, Hubei University of Medicine Shiyan 442000, China. 3. College of Veterinary Medicine, Sichuan Agricultural University Ya'an 625014, Sichuan, China. 4. Department of Microbiology, West China of Preclinical and Forensic Medicine, Sichuan University Chengdu 610041, China ; Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China. 5. Sichuan Vaccine Technology Co., Ltd. Chengdu 610041, Sichuan, China.
Abstract
OBJECTIVE: To study immunization procedures and preparation methods of specific IgY antibodies (IgY-Hp, IgY-IB) produced by hens immunized with Helicobacter pylori (Hp) bacterial antigen and recombinant Hp specific antigen IB, detect the inhibition effects on Hp growth and Hp urease activity, and study the effects of oral administration for treating Hp infection. METHODS: By using recombinant cholera toxin subunit B (rCTB) as an adjuvant, hens received intramuscular injection immunization for continuous 7 times at an interval of 14 days. Then, the eggs were collected; IgY was purified. RESULTS: On day 49 after hens were immunized, levels of two antibodies all reached 1:12800; after they were purified by Ammonium sulfate precipitation, their purity was over 80%. IgY-Hp could inhibit Hp growth and inhibit Hp urease activity; although in vitro, IgY-IB could not inhibit Hp growth but could inhibit Hp urease activity. The experiments in vivo found that when IgY-Hp or IgY-IB with sucralfate dual oral therapy was used to treat Hp infected mouse model, the cure rate all could reach 83.3%. CONCLUSION: According to immunization procedure, high titer specific IgY antibody (1:12800) can be obtained in 49 days and its titer remains stable. Oral administration of the specific IgY antibodies in Hp infected mice can reach a cure rate of 83.3%, and the antibodies are expected to become new drugs and therapeutic methods of targeted therapy against Hp infection.
OBJECTIVE: To study immunization procedures and preparation methods of specific IgY antibodies (IgY-Hp, IgY-IB) produced by hens immunized with Helicobacter pylori (Hp) bacterial antigen and recombinant Hp specific antigen IB, detect the inhibition effects on Hp growth and Hp urease activity, and study the effects of oral administration for treating Hp infection. METHODS: By using recombinant cholera toxin subunit B (rCTB) as an adjuvant, hens received intramuscular injection immunization for continuous 7 times at an interval of 14 days. Then, the eggs were collected; IgY was purified. RESULTS: On day 49 after hens were immunized, levels of two antibodies all reached 1:12800; after they were purified by Ammonium sulfate precipitation, their purity was over 80%. IgY-Hp could inhibit Hp growth and inhibit Hp urease activity; although in vitro, IgY-IB could not inhibit Hp growth but could inhibit Hp urease activity. The experiments in vivo found that when IgY-Hp or IgY-IB with sucralfate dual oral therapy was used to treat Hp infected mouse model, the cure rate all could reach 83.3%. CONCLUSION: According to immunization procedure, high titer specific IgY antibody (1:12800) can be obtained in 49 days and its titer remains stable. Oral administration of the specific IgY antibodies in Hp infected mice can reach a cure rate of 83.3%, and the antibodies are expected to become new drugs and therapeutic methods of targeted therapy against Hp infection.
Entities:
Keywords:
Helicobacter pylori; antibacterial effect; specific IgY
Authors: Andres Agurto-Arteaga; Astrid Poma-Acevedo; Dora Rios-Matos; Ricardo Choque-Guevara; Ricardo Montesinos-Millán; Ángela Montalván; Gisela Isasi-Rivas; Yudith Cauna-Orocollo; María de Grecia Cauti-Mendoza; Norma Pérez-Martínez; Kristel Gutierrez-Manchay; Ingrid Ramirez-Ortiz; Dennis Núñez-Fernández; Mario I Salguedo-Bohorquez; Stefany Quiñones-Garcia; Manolo Fernández Díaz; Luis A Guevara Sarmiento; Mirko Zimic Journal: Front Immunol Date: 2022-05-10 Impact factor: 8.786
Authors: Ximin Zeng; Huiwen Wang; Canghai Huang; Catherine M Logue; Nicolle L Barbieri; Lisa K Nolan; Jun Lin Journal: Front Immunol Date: 2021-04-02 Impact factor: 7.561